Imunon resumes at-the-market stock offering after previous suspension

Imunon, Inc.

On Sept 3, 2024, Imunon filed a new prospectus supplement to resume sales under the existing ATM agreement.
The ATM program had been suspended on July 30, 2024 via termination of the sales prospectus.
The ATM Agreement (May 2022, amended May 2024) with H.C. Wainwright remains in force.
Legal opinion on share validity from Covington & Burling filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.